NCT00002760View on ClinicalTrials.gov

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

August 31, 1996

Primary Completion Date

March 31, 2004

Study Completion Date

April 30, 2009

Conditions
Prostate Cancer
Interventions
DRUG

ketoconazole

400 mg PO tid for as long as treatment is effective

DRUG

therapeutic hydrocortisone

hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective

OTHER

Withdrawal of antiandrogen therapy

no drugs given

Trial Locations (2)

55455

University of Minnesota Cancer Center, Minneapolis

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER